• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Orthofix Medical Inc.

    4/11/25 2:49:36 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    Orthofix Medical Inc.

    (Name of Issuer)


    Common stock, $0.10 par value per share

    (Title of Class of Securities)


    68752M108

    (CUSIP Number)


    John A. Bartholdson
    Juniper Investment Company, LLC, 555 Madison Avenue, 24th Floor
    New York, NY, 10022
    (212) 339-8500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/09/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    Juniper Targeted Opportunity Fund, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,934,876.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    1,934,876.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    1,934,876.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    Juniper HF Investors II, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,934,876.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,934,876.00
    11Aggregate amount beneficially owned by each reporting person

    1,934,876.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    Juniper Targeted Opportunities, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    407,124.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    407,124.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    407,124.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    Juniper Targeted Opportunity Investors, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    407,124.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    407,124.00
    11Aggregate amount beneficially owned by each reporting person

    407,124.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    Juniper Multi-Strategy Fund, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    26,500.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    26,500.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    26,500.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    Juniper HF Investors, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,500.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,500.00
    11Aggregate amount beneficially owned by each reporting person

    26,500.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    Juniper Investment Company, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,386,500.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,386,500.00
    11Aggregate amount beneficially owned by each reporting person

    2,386,500.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IA



    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    Alexis P. Michas
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,386,500.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,386,500.00
    11Aggregate amount beneficially owned by each reporting person

    2,386,500.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    68752M108


    1 Name of reporting person

    John A. Bartholdson
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,386,500.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,386,500.00
    11Aggregate amount beneficially owned by each reporting person

    2,386,500.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common stock, $0.10 par value per share
    (b)Name of Issuer:

    Orthofix Medical Inc.
    (c)Address of Issuer's Principal Executive Offices:

    3451 Plano Parkway, Lewisville, TEXAS , 75056.
    Item 2.Identity and Background
    (a)
    This Schedule 13D is being filed by: (i) Juniper Targeted Opportunity Fund, L.P., a Delaware limited partnership ("Juniper Fund"). (ii) Juniper HF Investors II, LLC, a Delaware limited liability company and the general partner of Juniper Fund ("Juniper HF II"). (iii) Juniper Targeted Opportunities, L.P., a Delaware limited partnership ("Juniper Targeted Opportunities"). (iv) Juniper Targeted Opportunity Investors, LLC, a Delaware limited liability company and the general partner of Juniper Targeted Opportunities ("Juniper TO"). (v) Juniper Multi-Strategy Fund, L.P., a Delaware limited partnership ("Juniper Multi-Strategy"). (vi) Juniper HF Investors, LLC, a Delaware limited liability company and the general partner of Juniper Multi-Strategy ("Juniper HF"). (vii) Juniper Investment Company, LLC, a Delaware limited liability company and the investment advisor to Juniper Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy ("Juniper Investment Company"). (viii) Alexis P. Michas, as a managing member of each of Juniper HF II, Juniper TO, Juniper HF, and Juniper Investment Company; and (ix) John A. Bartholdson, as a managing member of each of Juniper HF II, Juniper TO, Juniper HF, and Juniper Investment Company.
    (b)
    555 Madison Avenue, 24th Floor, New York, New York 10022
    (c)
    The principal business of each of Juniper Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy is to invest in the capital stock of various companies. The principal business of Juniper HF II is to serve as the general partner of Juniper Fund. The principal business of Juniper TO is to serve as the general partner of Juniper Targeted Opportunities. The principal business of Juniper HF is to serve as the general partner of Juniper Multi-Strategy. Juniper Investment Company provides investment advisory and management services and acts as the investment manager of Juniper Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy. Each of Messrs. Michas and Bartholdson serves as managing member of Juniper HF II, Juniper TO, Juniper HF, and Juniper Investment Company.
    (d)
    During the past five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Each of Messrs. Michas and Bartholdson is a United States citizen.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 is hereby amended and supplemented by adding the following information: As of the date hereof, the Reporting Persons are deemed to beneficially own the Subject Shares as detailed in Items 1 and 5.
    Item 4.Purpose of Transaction
     
    Item 4 is hereby amended and supplemented by adding the following information. Between March 3, 2025, and April 4, 2025, Juniper Targeted Opportunity Fund, L.P. purchased 380,151 shares at an aggregate purchase price of approximately $6,119,974, which includes brokerage commissions, in the open market. Between March 8, 2025, and April 9, 2025, Juniper Targeted Opportunities, L.P. purchased 51,100 shares at an aggregate purchase price of approximately $747,153, which includes brokerage commissions, in the open market
    Item 5.Interest in Securities of the Issuer
    (a)
    The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference. (a) The percentages of ownership indicated in this Schedule 13D are calculated based on 39,022,492 Shares reported as outstanding as of February 21, 2025 (the "Record Date"), in the Issuer's Annual Report on Form 10-K for the quarterly period ended December 31, 2024, as filed with the United States Securities and Exchange Commission on February 25, 2025. As of the date of this Schedule 13D, the Reporting Persons collectively held an aggregate of 2,368,500 Shares, constituting approximately 6.1% of the Issuer's outstanding Shares as of the Record Date. As of the date of this Schedule 13D, each Reporting Person may be deemed to have direct beneficial ownership of the Shares as follows: (i) Juniper Fund beneficially owned 1,934,876 Shares, constituting approximately 5% of the Issuer's outstanding Shares as of the Record Date. (ii) Juniper Targeted Opportunities beneficially owned 407,124 Shares, constituting approximately 1% of the Issuer's outstanding Shares as of the Record Date. (iii) Juniper Multi-Strategy beneficially owned 26,500 Shares, constituting approximately 0.1% of the Issuer's outstanding Shares as of the Record Date. (iv) Juniper HF II, as the general partner of Juniper Fund, may be deemed to own beneficially (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the 1,934,876 Shares held by Juniper Fund, constituting approximately 5% of the Issuer's outstanding Shares as of the Record Date. Juniper HF II disclaims beneficial ownership of such Shares for all other purposes. (v) Juniper TO, as the general partner of Juniper Targeted Opportunities, may be deemed to own beneficially (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the 407,124 Shares held by Juniper Targeted Opportunities, constituting approximately 1% of the Issuer's outstanding Shares as of the Record Date. Juniper TO disclaims beneficial ownership of such Shares for all other purposes. (vi) Juniper HF, as the general partner of Juniper Multi-Strategy, may be deemed to own beneficially (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the 26,500 Shares held by Juniper Multi-Strategy, constituting approximately 0.1% of the Issuer's outstanding Shares as of the Record Date. Juniper HF disclaims beneficial ownership of such Shares for all other purposes. (v) Juniper Investment Company, as the investment advisor of Juniper Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy, may be deemed to own beneficially (as that term is defined in Rule 13-d under the Securities Exchange Act of 1934) the 2,368,500 Shares collectively and directly held by each of Juniper Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy, constituting approximately 6.1% of the Issuer's outstanding Shares as of the Record Date. Juniper Investment Company disclaims beneficial ownership of such Shares for all other purposes. (vi) Each of Messrs. Michas and Bartholdson, as the managing member of Juniper HF II, Juniper TO, Juniper HF, and Juniper Investment Company, may be deemed to own beneficially (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the 2,368,500 Shares held by Juniper Fund, Juniper Targeted Opportunities, Juniper Multi-Strategy, and Juniper Investment Company, constituting approximately 6.1% of the then outstanding Shares. Each of Messrs. Michas and Bartholdson disclaims beneficial ownership of such Shares for all other purposes.
    (b)
    Each of Juniper Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy has the sole power to vote or direct their respective vote of 1,934,876, 407,124 and 26,500 Shares and the sole power to dispose or direct the disposition of such Shares. Juniper HF II, Juniper TO, Juniper HF, Juniper Investment Company and each of Messrs. Michas and Bartholdson may be deemed to share with Juniper Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy, as applicable, the power to vote or to direct the vote and to dispose or to direct the disposition of such Shares.
    (c)
    Set forth on Exhibit A to this Schedule 13D is a list of transactions in the Shares effected by the Reporting Persons in the past sixty days. These transactions were all effected in the open market through a broker. Except for the foregoing, no other transactions in the Shares were affected by the Reporting Persons during the sixty days prior to the date of this Schedule 13D.
    (d)
    To the knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares that are the subject of this Schedule 13D.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The response to Item 3 is incorporated herein by reference. Except as described in this Schedule 13D or incorporated by reference in this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between any of the Reporting Persons or between any of the Reporting Persons and any other person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 99.A: Schedule of Transactions

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Juniper Targeted Opportunity Fund, L.P.
     
    Signature:/s/ John A. Bartholdson
    Name/Title:Managing Member of its General Partner, Juniper HF Investors II, LLC
    Date:04/11/2025
     
    Juniper HF Investors II, LLC
     
    Signature:/s/ John A. Bartholdson
    Name/Title:Managing Member
    Date:04/11/2025
     
    Juniper Targeted Opportunities, L.P.
     
    Signature:/s/ John A. Bartholdson
    Name/Title:Managing Member of its General Partner, Juniper Targeted Opportunity Investors, LLC
    Date:04/11/2025
     
    Juniper Targeted Opportunity Investors, LLC
     
    Signature:/s/ John A. Bartholdson
    Name/Title:Managing Member
    Date:04/11/2025
     
    Juniper Multi-Strategy Fund, L.P.
     
    Signature:/s/ John A. Bartholdson
    Name/Title:Managing Member of its General Partner, Juniper Targeted Opportunity Investors, LLC
    Date:04/11/2025
     
    Juniper HF Investors, LLC
     
    Signature:/s/ John A. Bartholdson
    Name/Title:Managing Member
    Date:04/11/2025
     
    Juniper Investment Company, LLC
     
    Signature:/s/ John A. Bartholdson
    Name/Title:Managing Member
    Date:04/11/2025
     
    Alexis P. Michas
     
    Signature:/s/ Alexis P. Michas
    Name/Title:Managing Member
    Date:04/11/2025
     
    John A. Bartholdson
     
    Signature:/s/ John A. Bartholdson
    Name/Title:Managing Member
    Date:04/11/2025
    Get the next $OFIX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    7/19/2023$27.00Buy
    BTIG Research
    3/4/2022$41.00 → $45.00Hold → Buy
    Stifel
    More analyst ratings

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Finegan Michael was granted 26,087 shares, increasing direct ownership by 83% to 57,391 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      6/23/25 4:19:38 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Director Paolucci Michael E was granted 18,841 shares, increasing direct ownership by 28% to 86,948 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      6/23/25 4:19:09 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Director Capps Vickie L was granted 18,841 shares, increasing direct ownership by 609% to 21,934 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      6/23/25 4:18:43 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Orthofix with a new price target

      Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

      1/22/25 7:47:50 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by Stifel with a new price target

      Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously

      11/8/24 8:23:19 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by ROTH MKM with a new price target

      ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously

      5/8/24 6:31:28 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bazaar Alan Lee bought $24,570 worth of shares (2,250 units at $10.92), increasing direct ownership by 8% to 30,983 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      6/5/25 5:11:05 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Amendment: Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

      4/A - Orthofix Medical Inc. (0000884624) (Issuer)

      5/14/25 4:34:50 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • President & CEO Calafiore Massimo bought $125,400 worth of shares (10,000 units at $12.54), increasing direct ownership by 4% to 234,603 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/12/25 7:14:09 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the global commercial launch of the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate represents the first commercially available device in the U.S. with a patented design for use in the TBT procedure to provide a limb preservation treatment option for addressing bony or soft tissue deformities or defects, such as diabetic ulcers. "I have been using the TrueLok Elevate System in my practice to treat patients with ulcers and other ischemic conditions and am pleased by the results I have observed so far," said Victor Anciano, M.D., a foot and ankle surgeon in Louisville,

      6/17/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance

    $OFIX
    SEC Filings

    See more
    • Orthofix Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

      8-K - Orthofix Medical Inc. (0000884624) (Filer)

      6/20/25 9:00:28 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Orthofix Medical Inc.

      SD - Orthofix Medical Inc. (0000884624) (Filer)

      5/30/25 4:33:26 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Orthofix Medical Inc.

      10-Q - Orthofix Medical Inc. (0000884624) (Filer)

      5/6/25 7:05:26 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Orthofix Announces Appointment of Vickie Capps to Board of Directors

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa

      3/12/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b

      8/15/24 5:52:00 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Names Stephanie Walsh Chief Human Resources Officer

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H

      7/16/24 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

      SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

      11/14/24 5:20:27 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Orthofix Medical Inc.

      SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

      11/13/24 5:03:21 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

      SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

      4/22/24 5:00:33 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Financials

    Live finance-specific insights

    See more
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix to Report First Quarter 2025 Financial Results

      Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O

      4/15/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance

      Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account

      2/25/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care